Gilead updates Phase 2 data for bladder cancer therapy Trodelvy
Justin Sullivan/Getty Images News


Announcing updated data from its Phase 2 TROPHY-U-01 study, Gilead Sciences (NASDAQ:GILD) said Friday that its antibody-drug conjugate Trodelvy showed efficacy across new indications in bladder cancer.
The FDA has already cleared Trodelvy under the agencyâs accelerated approval for certain patients with metastatic urothelial cancer (mUC) who have previously received platinum-containing chemotherapy and a checkpoint inhibitor.

The new data showed that Trodelvy led to an overall survival rate of 13.5 months in 38 patients with platinum-ineligible mUC after checkpoint inhibitor therapy.
Meanwhile, 41 patients with mUC whose disease progressed rapidly after platinum-based chemotherapy indicated 12.8 months of overall survival following treatment with Trodelvy plus Merckâs (MRK) pembrolizumab.
The company is awaiting data from its Phase 3 TROPiCS-04 study to convert its accelerated approval for Trodelvy into a full approval in bladder cancer.

Seeking Alpha contributor Daniel SchÃ¶nberger reaffirmed his Buy rating on Gilead (GILD) in January, arguing that the company âstill seems undervaluedâ given its growth prospects.